10 completed, 2 recruiting, 2 terminated, 1 withdrawn. 15 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 10, Recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Sarcoma, Synovial: new trials by email Literature Review of Sarcoma, Synovial trials Research Report on Sarcoma, Synovial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma TBI-1301, Cyclophosphamide, Fludarabine - Synovial Sarcomas | Phase 3 | Recruiting | Takara Bio Inc. | 5 | 2026-01-05 | 2026-09-28 |
| Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin Trabectedin discontinuation, Trabectedin continuation - Leiomyosarcoma, Liposarcoma | Phase 3 | Withdrawn | Italian Sarcoma Group | 2019-02-28 | 2019-05-13 | |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) LV305, G305, LV305-matching placebo - Synovial Sarcoma, Cancer | Phase 3 | Terminated | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 1 | 2018-09-18 | 2020-04-16 |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) AL3818, Dacarbazine, AL3818 or placebo - Alveolar Soft Part Sarcoma, Leiomyosarcoma | Phase 3 | Recruiting | Advenchen Laboratories, LLC | 325 | 2017-08-15 | 2026-02-25 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis - Sarcoma | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 133 | 2011-05-01 | 2014-08-08 |
| Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma trofosfamide, idarubicin, etoposide - Soft Tissue Sarcoma | Phase 3 | Completed | University Hospital Tuebingen | 195 | 2009-07-01 | 2022-11-08 |
| Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery - Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma | Phase 3 | Completed | Children's Oncology Group | 588 | 2007-02-05 | 2022-04-28 |
| Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma radiotherapy - Sarcoma | Phase 3 | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 216 | 2006-03-01 | 2021-03-18 |
| Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis conventional surgery, radiation therapy - Sarcoma | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 370 | 2004-08-01 | 2016-07-06 |
| Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma pegfilgrastim, doxorubicin hydrochloride, ifosfamide - Sarcoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 455 | 2003-04-01 | 2014-10-27 |
| Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma doxorubicin hydrochloride, ifosfamide - Sarcoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 780 | 1998-01-01 | 2012-01-20 |
| Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma doxorubicin hydrochloride, etoposide, ifosfamide - Sarcoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 1997-07-01 | 2013-09-17 |
| Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 1996-04-01 | 2012-07-11 |
| Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 350 | 1995-02-01 | 2014-08-08 |
Sarcoma (14) · Leiomyosarcoma (12) · Fibrosarcoma (10) · Histiocytoma, Malignant Fibrous (10) · Liposarcoma (10) · Neurofibrosarcoma (10) · Hemangiosarcoma (9) · Sarcoma, Alveolar Soft Part (7) · Hemangiopericytoma, Malignant (6) · Malignant mesenchymal tumor (5) · Rhabdomyosarcoma (5) · Chondrosarcoma, Extraskeletal Myxoid (4) · Dermatofibrosarcoma (2) · Endometrial Neoplasms (2)
Neoplasms by Histologic Type (15) · Neoplasms, Connective Tissue (15) · Neoplasms, Connective and Soft Tissue (15) · Neoplasms (14) · Neoplasms, Muscle Tissue (13) · Histiocytoma (10) · Neoplasms, Adipose Tissue (10) · Neoplasms, Fibrous Tissue (10) · Neoplasms, Nerve Tissue (10) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Neurofibroma (10) · Neuromuscular Diseases (10) · Peripheral Nervous System Diseases (10) · Peripheral Nervous System Neoplasms (10)
Doxorubicin (8) · Ifosfamide (7) · Radiotherapy (5) · Etoposide (2) · Filgrastim (2) · Chemotherapy, Adjuvant (1) · Combined Modality Therapy (1) · Cyclophosphamide (1) · Dacarbazine (1) · Diathermy (1) · Digoxin (1) · Idarubicin (1) · Midazolam (1) · Observation (1) · Radiation (1)
European Organisation for Research and Treatment of Cancer - EORTC (6) · Advenchen Laboratories, LLC (1) · Alliance for Clinical Trials in Oncology (1) · Children's Oncology Group (1) · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Italian Sarcoma Group (1) · National Cancer Institute (NCI) (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · Takara Bio Inc. (1) · University Hospital Tuebingen (1)
Canada (6) · Germany (6) · United Kingdom (6) · United States (6) · Spain (5) · Austria (4) · Belgium (4) · Denmark (4) · France (4) · Netherlands (4) · Slovakia (4) · Switzerland (4) · Italy (3) · Poland (3) · Hungary (2)
A.N. Van Geel, MD (1) · Aaron R Weiss (1) · Ewa Koscielniak, MD (1) · Ian R. Judson, MA, MD, FRCP (1) · James E. Butrynski, MD (1) · Laurence H. Baker, DO, FACOI (1) · Martin Robinson, MD (1) · Monika Sparber Sauer, MD (1) · Nguyen Binh Bui, MD (1) · Paul C. Lorigan, MD (1) · Penella J. Woll, MD, PhD (1) · Peter Pisters, MD (1) · Roberta Sanfilippo, MD (1) · Rolf D. Issels, MD, PhD (1)
PMID 17634494, PMID 18286501, PMID 20434400, PMID 22954508, PMID 24618336, PMID 24747207, PMID 28391003, PMID 29450452, PMID 30954717, PMID 31786124, PMID 32702309, PMID 32827353, PMID 33548339, PMID 34515544, PMID 34623899, PMID 34666214, PMID 36566574, PMID 37523624, PMID 38757485, PMID 39122389, PMID 39687431, PMID 41386267, PMID 42035475
U10CA098543 (2), 2009 (1), U10CA180830 (1), U10CA180886 (1)